Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety study of serlopitant for pruritus
2017-004211-40Phase 3Terminated
- Sponsor
- Menlo Therapeutics Inc.
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of serlopitant in prurigo nodularis (PN), atopic dermatitis (AD), psoriasis and 1 more, sponsored by Menlo Therapeutics Inc. Primary endpoint: Long-term safety of serlopitant. Started Jan 2018; status: terminated.
02
Drugs
serlopitant
03
Conditions
prurigo nodularis (PN)atopic dermatitis (AD)psoriasispruritus
Beyond the preview
Go deeper on 2017-004211-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004211-40.